Abstract
Up-regulation of neuronal KCNQ channels within the ventral tegmental area (VTA)–nucleus accumbens (NAc) reward pathway has emerged as an essential mechanism of stress resilience, and KCNQ channel openers show antidepressant activity in rodent models. Base on this work, we have conducted a proof-of-concept (POC) clinical trial of the KCNQ channel opener ezogabine in patients with major depressive disorder (MDD) with concurrent measurement of neurocircuit function using functional MRI (fMRI).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
